Clinical diagnosis of dementia

被引:36
作者
Robillard, Alain [1 ]
机构
[1] Univ Montreal, Hop Maison Neuve Rosemont, Dept Med, Div Neurol, Montreal, PQ, Canada
关键词
dementia; diagnosis; Alzheimer; Lewy body; frontotemporal; vascular; behavior;
D O I
10.1016/j.jalz.2007.08.002
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
This paper presents recommendations deriving from the Third Canadian Consensus Conference on the Diagnosis and Treatment of Dementia, concerning the clinical diagnosis of dementia. There are currently no universally accepted biological or radiological markers of dementia. In the absence of these, the diagnosis of dementia remains a clinical exercise aiming to integrate all available clinical and laboratory information. It is proposed that the currently used National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS/ADRA) criteria for diagnosis of Alzheimer's disease (AD) be retained. The currently available vascular dementia (VaD) diagnostic criteria have variable accuracy. An integrative approach to VaD diagnosis based on all the available evidence (history, vascular risk factors, physical exam, clinical course, neuroimaging, cognitive impairment pattern) is recommended. The separation of Lewy body dementia (DLB) from Parkinson's disease dementia (PDD) is based on the dominant clinical presenting feature of each syndrome, and relies on the duration of this feature: long duration of parkinsonian "motor" syndrome preceding dementia for PDD versus early/initial dementia accompanied by extrapyramidal symptoms for DLB. It is recognized that it is impossible clinically to characterize DLB with (pathologically) coexisting AD changes. The Frontotemporal group of dementia syndromes are discussed in regards to their typical clinical pictures, recognizing that their neuropathological substrate are not predictable from their mode of presentation. Finally, the particular rapid time sequence of evolution of the dementias due to prior disease is recognized as the clinically most useful distinguishing feature of these syndromes. (c) 2007 The Alzheimer's Association. All rights reserved.
引用
收藏
页码:292 / 298
页数:7
相关论文
共 78 条
[1]  
*AM PSYC ASS, 1987, DIAGN STAT MAN MENT
[2]  
American Psychiatric Association, 1994, DIAGN STAT MAN MENT
[3]   Clinicopathologic studies in cognitively healthy aging and Alzheimer disease - Relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype [J].
Berg, L ;
McKeel, DW ;
Miller, JP ;
Storandt, M ;
Rubin, EH ;
Morris, JC ;
Baty, J ;
Coats, M ;
Norton, J ;
Goate, AM ;
Price, JL ;
Gearing, M ;
Mirra, SS ;
Saunders, AM .
ARCHIVES OF NEUROLOGY, 1998, 55 (03) :326-335
[4]   RELIABILITY AND VALIDITY OF NINCDS-ADRDA CRITERIA FOR ALZHEIMERS-DISEASE - THE NATIONAL-INSTITUTE-OF-MENTAL-HEALTH GENETIC INITIATIVE [J].
BLACKER, D ;
ALBERT, MS ;
BASSETT, SS ;
GO, RCP ;
HARRELL, LE ;
FOLSTEIN, MF .
ARCHIVES OF NEUROLOGY, 1994, 51 (12) :1198-1204
[5]   Diagnosis of Creutzfeldt-Jakob disease -: Effect of clinical criteria on incidence estimates [J].
Brandel, JP ;
Delasnerie-Lauprêtre, N ;
Laplanche, JL ;
Hauw, JJ ;
Alpérovitch, A .
NEUROLOGY, 2000, 54 (05) :1095-1099
[6]  
BRUN A, 1994, J NEUROL NEUROSUR PS, V57, P416
[7]   CSF detection of the 14-3-3 protein in unselected patients with dementia [J].
Burkhard, PR ;
Sanchez, JC ;
Landis, T ;
Hochstrasser, DF .
NEUROLOGY, 2001, 56 (11) :1528-1533
[8]   Sensitivity of 14-3-3 protein test varies in subtypes of sporadic Creutzfeldt-Jakob disease [J].
Castellani, RJ ;
Colucci, M ;
Xie, Z ;
Zou, W ;
Li, C ;
Parchi, P ;
Capellari, S ;
Pastore, M ;
Rahbar, MH ;
Chen, SG ;
Gambetti, P .
NEUROLOGY, 2004, 63 (03) :436-442
[9]  
CATHALA F, 1979, REV NEUROL, V135, P439
[10]   Mild cognitive impairment and cognitive impairment, no dementia: Part A, concept and diagnosis [J].
Chertkow, Howard ;
Nasreddine, Ziad ;
Joanette, Yves ;
Drolet, Valerie ;
Kirk, John ;
Massoud, Fadi ;
Belleville, Sylvie ;
Bergman, Howard .
ALZHEIMERS & DEMENTIA, 2007, 3 (04) :266-282